Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 34Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 25Multiple Myeloma 20Recurrence 19Leukemia, Myeloid, Acute 19Neoplasm Metastasis 17Colorectal Neoplasms 16Lymphoma, Non-Hodgkin 15Melanoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia 13Ovarian Neoplasms 12Lymphoma, Follicular 12Carcinoma, Renal Cell 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Urinary Bladder Neoplasms 10Lung Neoplasms 10Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Hematologic Neoplasms 9Carcinoma, Hepatocellular 9Adenocarcinoma 9Stomach Neoplasms 8Small Cell Lung Carcinoma 8Prostatic Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8

Interventions

pembrolizumab 1Melphalan 1Ipilimumab 1Dacarbazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Has announcements × Uveal Melanoma × Clear all
NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Immunocore Ltd

Phase 2 Completed
378 enrolled 15 charts 1 FDA
Dermatologic

Uveal Melanoma, Melanoma

NCT02678572 2023-12-21

FOCUS

Delcath Systems Inc.

Phase 3 Completed
102 enrolled 1 FDA
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡